Cytosorbents (CTSO) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTSO shares.
View CTSO analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price objectives for Cytosorbents' stock. Their CTSO share price forecasts range from $4.00 to $5.50. On average, they predict the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 174.6% from the stock's current price.
View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts.

Cytosorbents' stock was trading at $1.55 at the beginning of 2023. Since then, CTSO stock has increased by 11.6% and is now trading at $1.73.
View the best growth stocks for 2023 here.

Cytosorbents saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,220,000 shares, an increase of 19.6% from the August 31st total of 1,020,000 shares. Based on an average daily volume of 66,000 shares, the days-to-cover ratio is currently 18.5 days. Currently, 3.2% of the company's stock are sold short.
View Cytosorbents' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CTSO earnings forecast.

Cytosorbents Co. (NASDAQ:CTSO) posted its quarterly earnings data on Tuesday, August, 1st. The medical research company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.03. The medical research company earned $9.42 million during the quarter, compared to analyst estimates of $11.03 million. Cytosorbents had a negative net margin of 72.71% and a negative trailing twelve-month return on equity of 82.93%.

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTSO stock can currently be purchased for approximately $1.73.

Cytosorbents (NASDAQ:CTSO) has a market capitalization of $76.74 million and generates $34.69 million in revenue each year. The medical research company earns $-32,810,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

The company employs 198 workers across the globe.

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650.